Texas Tech University Health Sciences Center

Jerry H. Hodge School of Pharmacy

In cooperation with

Texas Tech University

Rawls College of Business

PharmD / MBA Program 2020 – 2021





1

Table of Contents

Introduction and Program History	
Application Information	4
PharmD / MBA Dual Degree Program	5
MBA Course Descriptions	6
Appendix with required forms	8

Program Vision Statement

Our vision is to become recognized as the pre-eminent PharmD/MBA dual degree program in the U.S.

Program Mission Statement

The mission of the PharmD/MBA program is to: (1) prepare pharmacy students to meet the increasing challenges of an evolving health care industry and to (2) educate those students to become future health care leaders.

Program Director's Message

The Pharm.D/MBA program provides opportunities to selected students to develop their leadership skills as we rapidly change our health care delivery system. The Health **Organization Management** concentration encourages greater exploration of subject matter that is important to the future of pharmacy and health care. Our students will acquire important skills that will be used to shape the future of health care delivery. This program is unique in that students get to be part of a joint effort that *emphasizes the co-dependency of* patient care delivery and the business models that support that care. As a Pharm.D/MBA student, you have been selected to be the future of pharmacy practice leadership. We are proud to be able to offer this unique program and we know that you will be proud to be one of our future graduates.

Dr. Roland A. Patry Program Director

Introduction and Program History

PHARM.D / MBA PROGRAM

The idea of a Pharm.D-MBA program was born in early 2006 in discussions between several faculty at the Texas Tech University Rawls College of Business and the Texas Tech University Health Science Center, School of Pharmacy (now the Jerry H. Hodge School of Pharmacy). The central theme to the discussions was the need to develop and train the future leaders of the profession. The Health Organization Management concentration within the MBA program matched what the pharmacy faculty believed were the necessary areas of focus to develop strong leaders in health care organizations.

The curriculum emerged after several rounds of negotiation between the programs keeping in mind the accreditation requirements of business and pharmacy. The curricular design model was determined after reviewing other Pharm.D-MBA programs matched with the teaching schedules and course prerequisites. Rather than adopting the various models currently in use throughout the U.S., the faculty chose to use a dual-degree approach and integrate both programs into a typical 4-year course of study. Since the program was structured to be a dual-degree, it was essential that all of the approved content for both degree plans be met.

The initial plan was to create several tracks for Pharm.D students to obtain the MBA. The first track would be to offer the opportunity of taking the MBA coursework to rising P-2 and rising P-3 students with the goal to phase out the P-3 program and only retain the rising P2 program. This track required the development of separate curricula to ensure that all requirements for both the Pharm.D and MBA were met. The first students began class in the summer 2009. The problems of managing the P-3 program soon became apparent and this track ended with the graduation of the first class.

The second track was viewed as the most desired by the faculty at both colleges. This involved offering the program to what we called P0-P1 students (accepted into pharmacy school but not currently enrolled in pharmacy courses as well as rising P2 students). The P0 students would begin MBA coursework in the summer prior to enrollment in the pharmacy school. The rising P2 students would begin their MBA program in the summer between the P1 and P2 years. The summer 2010 class was the first under this track.

Prior to 2019, summer MBA classes for the second-program year students were held at one of four School of Pharmacy locations. Although the program was overall a positive experience, issues with course delivery software led to discussions about alternative ways to teach the second year of the MBA program. In early 2019, a decision was reached that for the second summer program year, courses would be delivered on-line eliminating the need for students to be located near School of Pharmacy campuses. This also meant that student could remain near their home or in any location that had Internet capabilities.

In the fall 2019, after reviewing the success of the on-line course delivery for the second summer program year, faculty from the business and pharmacy colleges began a discussion to transform all health-related, dual-degree programs into an all on-line degree offering. As approved, the first offering of an on-line PharmD-MBA program will the summer 2020 entering class.

At the May 2020 graduation, over 100 pharmacy students will have received their PharmD-MBA degrees. With current enrollments, the Texas Tech PharmD-MBA program is the largest of its kind in the U.S. The Texas Tech PharmD-MBA program continues to fulfill a significant need to train tomorrow's pharmacy leaders.

Application Information

******Applicants for the Pharm.D/MBA Dual Degree Program MUST have a prior baccalaureate or higher degree to be admitted into the program**

The TTUHSC School of Pharmacy will usually require completion of a Pharm.D/MBA application form by February 15 of each year. A Pharm.D/MBA selection committee will review the academic achievement of each candidate and forward a recommendation to the Rawls College of Business and HOM program. Students should delay completing the Rawls College of Business applications until a determination of School of Pharmacy (SOP) recommendation has been made. If the Committee does not recommend a student apply to the MBA program, the SOP program coordinator will counsel the The Rawls College of Business and the School of Pharmacy may limit the number of pharmacy students that are allowed to enroll in the MBA.

Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy Notice of Intent

- 1. P-0 and P1 students desiring to enroll in the Pharm.D/MBA program must complete a Pharm.D/MBA application form
- 2. P-0 and P1 students desiring to enroll in the Pharm.D/MBA program must sign an acknowledgement or disclosure form, signifying an understanding of special curricular requirements for enrolling in the program.

The PharmD/MBA application form and the acknowledgement forms for P0 and P1 students are compiled in an appendix at the end of this document.

Page 9: PharmD / MBA application

Page 10: P0 acknowledgement form

Page 11: P1 acknowledgement form

Please send completed forms to: Dr. Roland Patry at roland.patry@ttuhsc.edu

Rawls College of Business Application

The following applications are due by **May 1** of the year of admission. The admission process for the Rawls College of Business MBA program (HOM) is comprised of a single application that combines the requirements for the Graduate School and the Business School:

Graduate School / Business School Application

1. Electronic application at: <u>http://www.depts.ttu.edu/gradschool/admissions/howtoapply.php</u>

- 2. Requires a \$65.00 fee
- 3. Official transcripts for all schools attended
- 4. GMAT scores: WAIVED FOR PHARM.D/MBA APPLICANTS
- 5. Submit a current resume

6. Submit two letters of recommendation (can be the same letters used for the PharmD application) NO essay is required.

		for student	PharmD-MBA Dual Degree ts classified as P0 or P1 for entering	•
) Summer S Summer 1		rs (Note: P1 MB/	A students will take between their P	and P2 years- P0 students take before their Fall P1 year)
Caninor	ISQS 5345	3 SCH	Statistical Concepts for Business an	Management (on-line)
	HOM 5307 *	3 SCH	Managing Healthcare Organizations	
	HOM 5308*	3 SCH	Healthcare Operations Management	
	ACCT 5301	3 SCH	Financial and Managerial Accounting	
	ISQS 5330	3 SCH	Decision Theory & Business Analytic	s (on-line)
Fall Semes	ster - 20 SCH			
Wk Block	P0 Preparation for Fall Phar 1440 4 SCH		on/Boot Camp dations of Therapeutics	
WK BIOOK	Phar 1430 - 4 SCH		dations in Pharmacy and Patient Assessme	nt with Lab
	Phar 1460 3 SCH		nce and Calculations	
	Phar 1432 - 4 SCH		unology and Microbiology + Clinical Immuni	ations Lab
	Phar 1101. 0 SCH		Pharmacy Practice I	
	phar 1220 2 SCH Phar 1250 - 2 SCH	Clinical Correlati	Pharmacy Practice	
	Co-curricular/Inter-profe			
Spring Ser	mester - 19 SCH			
Wk Block	Phar 1461 - 4 SCH		ulatioms & Compounding with Lab	
	Phar 1431 - 4 SCH		dations II with Pt. Assessment and Lab	
	Phar 1441 - 4 SCH Phar 1251, 2 SCH	Principles of Dru Clinical Correlati	ug Structure and Action	
	Phar 1251. 2 SCH Phar 1101 - 1 SCH		ions 2 ifessional Practice Experiences	
	Co-curricular/Inter-profe			
/k Blocks	1st 8-Weeks			2nd 8-Weeks
	Phar 1233 - 2 SCH	Principles of Dis	sease	Phar 1240 - 2 SCH App.Med. Chemistry
-P2 Summ nmer 2	er Sessions: 15 credit	S		
	MGT 5371	3 SCH	Managing Org. Behavior & Organizat	ional Design (on-line)
	MKT 5360	3 SCH	Marketing Concepts and Strategies (
	BECO 5310	3 SCH	Economic Business Analysis (on-lin	e)
	FIN 5320	3 SCH	Financial Mgt Concepts (on-line)	
	HOM 5309*	3 SCH	HOM IV: Integrated Healthcare Opera	tions (capstone-online)
Fall Semes	ster - 20 SCH Phar 2420 - 4 SCH	Principles of Sel	lf-Care, Health, & Wellness Promotion	
WK DIOCK	Phar 2402 - 4 SCH	•	apeutics and Practice II-Renal/Respiratory	
	Phar 2220 - 2 SCH	Applied Patient (
	Phar 2210- 2 SCH		ch and Drug Literature Evaluation	
	Phar 2218 - 2 SCH		ement I: Health Systems and Policy	
	Phar 2250- 2 SCH Phar 2401 - 4 SCH	Clinical Correlati	apeutics and Practice I- Cardiovascular	
	Phar 2101 - 0 SCH		(No Credit This Semester - Clerkship Runs	All Year)
	Co-curricular/Inter-profe			,
	mester - 21 SCH: 22 S			
Wk Block	Phar 2460- 4 SCH		ed Pharmacokinetics	
	Phar 2419- 4 SCH Phar 2219- 2 SCH		I: Leadership, Law and Ethics (Do not enrol Law (only MBA students enroll in this cours	. MBA students enroll in PHAR 5372 and PHAR 2219 instead)
	Phar 2403 - 4 SCH		tice and Therapeutics III -Endocrine, Repro	
	Phar 5372 - 3 SCH	Advanced Lead	dership and Ethics (substitute for MGT 5	372)
	Phar 2404- 4 SCH		apeutics and Practice IV- Infectious Disease	s
	Phar 2261 - 2 SCH		Specialty Pharmaceuticals with Lab	
	Phar 2251 - 2 SCH	Clinical Correlea		L Yoor)
	Phar 2101 - 1 SCH Co-curricular/Inter-profe		p (Credit This Semester - Clerkship Runs A ivity requirement	
2-P3 Summ	er Sessions: 0 credits		wy requirement	
Fall Semes	ster - 12 <u>SCH + P3 Cl</u>	erkships + Electiv	ves (MBA students take 10 SCH plus	clerkships and electives)
Wk Block				
	Phar 3405 - 4 SCH	0	erapeutics and Practice V: Neuro and	5
	Phar 3218 - 2 SCH Phar 3406 - 4 SCH		agement (offered in 2020-2021-MBA stude apeutics and Pratice VI: GI Hepatic, Nutritio	ents do not take: will transfer FIN 5320 from Rawls College of Business)
	Phar 3250 - 2 SCH	Clinical Correlati		, obony and womood
/k Blocks	Electives			
	Must take a total of 3	courses of elective	es over the year	
	Co-curricular/Inter-profe			
	IPPE Clerkships (subs			
		Clerkships+ Elea		
	mester - 12 SCH + P3			
	mester - 12 SCH + P3 Phar 3420 - 4 SCH	Clinical Toxicolo	ogy & Drug Safety & Abuse	
	mester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH	Clinical Toxicolo Practice Manage	ement III: Institutional and Community Phar	
	mester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH Phar 3407 - 4 SCH	Clinical Toxicolo Practice Manage Integrated Thera	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema	
Wk Block	mester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH Phar 3407 - 4 SCH Phar 3215 - 2 SCH	Clinical Toxicolo Practice Manage	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema	
	nester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH Phar 3407 - 4 SCH Phar 3215 - 2 SCH Electives	Clinical Toxicolo Practice Manage Integrated Thera Clinical Correlati	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema ions 6	
Wk Block	Phare 3420 - 4 SCH Pare Phare 3420 - 4 SCH Phare 3420 - 4 SCH Phare 3219 - 2 SCH Phare 3407 - 4 SCH Phare 3215 - 2 SCH Electives Must take a total of 3 and	Clinical Toxicolo Practice Manage Integrated Thera Clinical Correlati	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema ions 6 as over the year	
Wk Block	nester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH Phar 3407 - 4 SCH Phar 3215 - 2 SCH Electives	Clinical Toxicolo Practice Manage Integrated Thera Clinical Correlati courses of elective essional (IPE) activ	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema ions 6 so over the year ivity requirement	
Wk Block K Blocks	mester - 12 SCH + P3 Phar 3420 - 4 SCH Phar 3219 - 2 SCH Phar 3407 - 4 SCH Phar 3215 - 2 SCH Electives Must take a total of 3 Co-curricular/Inter-profi IPPE Clerkships (subs	Clinical Toxicolo Practice Manage Integrated Thera Clinical Correlati courses of elective essional (IPE) activi stitute for HOM 538	ement III: Institutional and Community Phar apeutics and Practice VII:Oncology & Hema ions 6 so over the year ivity requirement	tology

MBA Course Descriptions*

*MBA courses only. Please see the TTUHSC Jerry H. Hodge School of Pharmacy catalogue for the PharmD requirements and course descriptions

ACCT 5301. Financial and Managerial Accounting (3:3:0,0)

Examines the objectives, structure, and substance of financial reports and the use of accounting in the management of an organization.

FIN 5320. Financial Management Concepts (3:3:0,O)

Essential financial management concepts with applications to financial decision making in organizations. Special emphasis on cases and computer financial models.

ISQS 5345. Statistical Concepts for Business and Management (3:3:0,O)

Statistical applications using the personal computer with emphasis on proper presentation and interpretation of statistics in managerial settings. Topics include descriptive statistics, graphical methods, estimation, testing, regression, forecasting, and quality control.

HOM 5307. Managing Healthcare Operations (3:3:0,O)

Examines fundamental and contemporary issues in management of costs and payments in the healthcare industry. (Requires a grade of B or better)

HOM 5308. Healthcare Operations and Quality (3:3:0,O)

A systems-based view of healthcare organizations emphasizing evaluation, measurement, and quality issues. (Requires a grade of B or better)

ISQS 5330. Decision Theory and Business Analytics (3:3:0,O)

Provides an overview of business analytics and examines normative and behavioral theories that drive decisionmaking.

MKT 5360. Marketing Concepts and Strategies (3:3:0,O)

Examines marketing functions, the institutions which perform them and the study of marketing planning, strategy, and tactics. Includes the organization, execution, and control of the marketing effort.

HOM 5309. HOM IV: Integrated Healthcare Operations (3:3:0,O)

Analyzes and examines core healthcare operational and management issues from a legal perspective through the use of targeted cases and projects. (Requires a grade of B or better)

BECO 5310. Domestic/Global Business Conditions in Health Care (3:3:0,O)

Studies markets in which firms compete within the context of a global supply chain, including markets for goods and services, financial markets, and labor. Emphasizes how the interactions of these markets affect the formulation and implementation of business strategies.

MGT 5371. Managing Organizational Behavior & Organizational Design (3:3:0,O)

Examines management of individual, interpersonal, group and intergroup relations, organizational design, and the organization's role in a rapidly changing environmental and global context.

PHAR 2219. MBA Pharmacy Law (2:4:0,F)

Prerequisites: P-2 student status, enrollment in the PharmD/MBA program or with permission of the teaching team. The study of federal and Texas statutes and rules, which regulate the practice of pharmacy and drug distribution. (Course runs over 8 weeks, see syllabus for schedule)

PHAR 5372. Advanced Leadership & Ethics (3:0:1,F)

Prerequisites: P-2 student status, enrollment in the PharmD/MBA program or with permission of the teaching team. Students will explore a number of current theories of leadership in this course. Instructional methods such as lectures, group and individual exercises, and case studies will be used to illustrate how specific principles of leadership are applied in the administration of healthcare institutions, including how these are impacted by gender, culture, and ethical behavior.

Appendix

PharmD MBA application and P0 and P1 Acknowledgement forms



PHARMD----MBA APPLICATION FORM

All currently enrolled or accepted students to the TTUHSC School of Pharmacy MUST complete this application form before submitting any applications or other documents to the TTU Rawls College of Business. A Review Committee of faculty and professional staff will review this application to determine the number of applicants that will be recommended by the TTUHSC School of Pharmacy. The Rawls College of Business Graduate Program determines their own admissions standards and applicants recommended by the School of Pharmacy may or may not be accepted by the Rawls College of Business.

NAME				
Last Name/Family Na	me			
First Name				
Middle				
EDUCATION				
Previous Degree (s) and University				
MAILING ADDRESS				
Street Address				
City/State				-
Zipcode				
Current Email				-
TELEPHONE				
Home Telephone	Area code ()		—
Cellphone	Area code ()		_
CURRENT ADDRESS AN	ND/OR TELEPHC	ONE GOOD UNTIL:	Month	Day



PHARMD-MBA P0 ACKNOWLEDGEMENT FORM

Students admitted to the PharmD/MBA program are expected to complete the requirements of both degree programs within a 4 year period of time. School of Pharmacy students who have not started the P-1 year (known as PO applicants) but desiring to pursue the MBA program will be required to begin the MBA the summer prior to actually starting the Pharm.D program.

Students who disenroll from the MBA program are still enrolled in the Pharm.D degree program; however, because of the dual degree plan for the PharmD/ MBA, each individual record will be evaluated to determine if Pharm.D courses that were waived will now be required for the PharmD degree. As a result, Pharm.D students may have delayed graduation until the degree requirements are completed.

I acknowledge that I have read and understand the above implications of my acceptance into the PharmD-MBA program as a PO applicant to the TTUHSC School of Pharmacy.

Printed Name	 	 	
Signature	 	 	



PHARMD-MBA P1 ACKNOWLEDGEMENT FORM

Students admitted to the PharmD/MBA program are expected to complete the requirements of both degree programs within a 4 year period of time. School of Pharmacy students who have not started the P-2 year (known as P1 applicants) but desiring to pursue the MBA program will be required to begin the MBA the summer prior to actually starting the P2 year.

Students who disenroll from the MBA program are still enrolled in the Pharm.D degree program; however, because of the dual degree plan for the PharmD/ MBA, each individual record will be evaluated to determine if Pharm.D courses that were waived will now be required for the PharmD degree. As a result, Pharm.D students may have delayed graduation until the degree requirements are completed.

I acknowledge that I have read and understand the above implications of my acceptance into the PharmD-MBA program as a P1 applicant to the TTUHSC School of Pharmacy.

Printed Name	 	
Signature	 	